This work was funded by Science Foundation Ireland (SFI 08/RFP/BMT1689), the Health Research Board in Ireland [HRA-POR/2012/4 and HRA-POR-2015-1145] and Royal City of Dublin Hospital Trust.

The experiments outlined in this protocol were carried out using the attenuated H37Ra strain of Mtb, which can be handled in a Containment Level 2 laboratory. All manipulations of live mycobacteria were carried out in Class II biological safety cabinet (BSC). Experimental procedures were designed to minimize the generation of aerosols. Eukaryotic cell culture (THP-1 cells) was also carried out in a Class II BSC. The laboratory carried out a risk assessment and ensured that all procedures were carried out in line with institutional and national biological safety regulations. The human monocytic THP-1 cell line was used to perform the method as described (step 1). Cells are differentiated into macrophages following stimulation with phorbol 12-myristate 13-acetate (PMA) before infection with mycobacteria.
1. Cell culture
<ol>
	<li>Propagate H37Ra seed stock to log phase in Middlebrook 7H9 (MB) broth supplemented with albumin-dextrose-catalase (ADC) enrichment (10%) and 0.05% polysorbate 80. Store H37Ra stock in 1 mL aliquots in a -80 &#176;C freezer for up to 1 year.</li>
	<li>Thaw a 1 mL vial of Mtb-H37Ra and transfer it to a T25 flask with a filter cap containing 9 mL of MB supplemented broth approximately 1 week before the planned experiment. Incubate at 37 &#176;C for 5-7 days in a static incubator.</li>
	<li>Grow THP-1 cells in RPMI-1640 supplemented with non-heat killed 10% fetal calf serum (complete (c)RPMI) in a T75 flask in a CO2 humidified incubator at 5% CO2/37 &#176;C and subculture twice per week to maintain a density of less than 1 x 106 cells/mL.</li>
	<li>Differentiate THP-1 cells into macrophages 3 days before infection by gently pipetting cells several times using a serological pipette in T75 flasks to disperse any clumps and place them in a 50 mL conical tube.</li>
	<li>Centrifuge cells at 300 x g for 10 min at room temperature, decant off the supernatant, and gently resuspend the pellet in 2 mL of RPMI. Perform cell count to estimate cells/mL.</li>
	<li>Seed 2 mL of THP-1 macrophages in 12-well tissue culture plates at a density of 100,000 cells/mL in cRPMI with 100 ng/mL PMA for 72 h. Remove PMA-containing medium from cells and replenish with fresh cRPMI before Mtb infection.</li>
	<li>Set up individual plates for each time point required.</li>
	<li>Seed cells at the same density (100,000 cells/mL) in 2-well glass chamber slides to determine the multiplicity of infection (MOI).</li>
	<li>Place in a 5% CO2 humidified incubator for 3 days at 37&#8239;&#176;C.</li>
</ol>
2. Quantification of Mtb uptake
<ol>
	<li>Determination of Mtb uptake by macrophages (MOI)
	<ol>
		<li>Set up the Class II biological safety cabinet (BSC) on the day of infection and work on two layers of tissue paper to catch any spills. Set up waste discard containers according to local regulations.</li>
		<li>Remove 6-8 mL of mycobacterial culture from the T25 flask and transfer it into a 15 mL polypropylene tube. 
		NOTE: Smaller volume tubes can be used for smaller experiments.</li>
		<li>Centrifuge the tube in a benchtop centrifuge at room temperature for 10 min at 2890 x g.</li>
		<li>Carefully remove the tube from the centrifuge and transfer it to the biological safety cabinet. Wait 1 min to allow the bacteria to settle.
		<ol>
			<li>Pour off the supernatant into the disinfectant discard container, recap tube, and resuspend the bacteria in the remaining medium by tapping the side of the tube. Wait 1 min to allow the bacteria to settle.</li>
		</ol>
		</li>
		<li>Add 2 mL of pre-warmed cRPMI, mix gently, and transfer to a 50 mL conical tube.</li>
		<li>Resuspend the mycobacteria very carefully using a 25 G needle and 5 mL syringe. To resuspend, draw up the mycobacteria suspension into the syringe and eject very gently down the sidewall of the tube to minimize aerosol production. Repeat 6-8 times. 
		NOTE: Exercise utmost caution as this is a high-density culture of mycobacteria. To avoid the risk of needle stick injury, use blunt needles where possible, and Luer lock syringes.</li>
		<li>Dispose of the needle and syringe in a sharps container in the BSC.</li>
		<li>Transfer the suspension to a 2 mL microfuge tube (with screw-on cap) and centrifuge at room temperature for 3 min at 100 x g to pellet any remaining clumps. Return the tube to the safety cabinet and wait 1 min to allow the bacteria to settle.</li>
		<li>Transfer the top 1-1.5 mL of the supernatant to a new tube. Discard the original tube in the waste bucket containing disinfectant. Mix well and add various amounts of the mycobacterial suspension (e.g., 5, 25, 50, 150 &#181;L) to the 2-well glass chamber slides and incubate for 3 h in a CO2 incubator at 37 &#176;C.</li>
	</ol>
	</li>
	<li>Staining for acid fast bacteria (AFB) 
	NOTE: After 3 h incubation, the macrophages are washed and fixed with paraformaldehyde to inactivate mycobacteria. The slides are then stained using a Modified Auramine O kit (see Table of Materials) to estimate mycobacteria phagocytosed per cell. Due to their waxy cell wall, mycobacteria retain the Auramine dye after an acid-alcohol wash. The macrophage nuclei are then counter-stained with Hoechst. This method allows for the number of phagocytosed bacteria per cell to be counted and is used to determine the multiplicity of infection (MOI) of the macrophages.
	<ol>
		<li>Remove the medium from the glass chamber slide after pipetting up and down three times to dislodge bacteria that have not been phagocytosed.</li>
		<li>Wash once with 2 mL of room temperature PBS.</li>
		<li>Store stocks of 4% paraformaldehyde, dissolved in PBS in aliquots at -20 &#176;C for up to 6 months. Thaw an aliquot of 4% paraformaldehyde immediately before use. Dilute to 2% paraformaldehyde with PBS and add 2 mL per well.</li>
		<li>Incubate for 10 min at room temperature. The glass chamber slide can be removed from the safety cabinet at this stage for staining.</li>
		<li>Wash the slide under a gentle stream of tap water.</li>
		<li>Dispense enough Auramine onto the slide to cover the cells using a plastic transfer pipette and incubate for 1 min at room temperature in the dark (cover with aluminum foil).</li>
		<li>Wash excess dye off the slide with tap water and add the decolorizer/quencher for 1 min in the dark.</li>
		<li>Wash off the excess with tap water and incubate for 15 min at room temperature with Hoechst 33342 (10 &#181;g/mL in PBS) in the dark.</li>
		<li>Wash off the Hoechst stain with tap water, remove the chambers, drain excess water from the slide, add a drop of antifade and coverslip, and air dry.</li>
		<li>Examine the slide under the fluorescent microscope using the 100x oil objective. Mycobacteria will fluoresce green under the FITC filter. The nuclei fluoresce blue under the DAPI filter (Figure 1C).</li>
		<li>Determine the MOI by counting the number of mycobacteria phagocytosed per cell and the percentage of cells infected.</li>
		<li>Calculate the volume of mycobacterial suspension needed to achieve the required MOI based on the surface area of a well in the plate; for example, the surface area of the glass chamber slides used in this experiment is 4 cm2. Low MOI (approximately 1-2 bacilli/cell) is desirable for experiments conducted over several days (e.g., 5 days).</li>
	</ol>
	</li>
	<li>Infection of macrophages
	<ol>
		<li>Mix the mycobacteria suspension well and add the amount needed to the cells on 12-well plates once the volume required to achieve the desired MOI has been determined.</li>
		<li>Incubate at 37 &#176;C for 3 h to allow mycobacteria to be phagocytosed.</li>
		<li>Remove extracellular bacteria by washing the wells with either warm RPMI or HBSS several times.</li>
		<li>Lyse the macrophages in one well (3 h sample) to determine the percentage time to positivity (TTP) of the initial inoculum (3 h sample) as outlined in step 3 below.</li>
		<li>Add fresh cRPMI and the required drug doses or vehicle control to the remaining wells, incubate the plates in the CO2 incubator at 37 &#176;C for the time necessary (dependent on the experimental design but usually at several intervals between 1 to 8 days).</li>
	</ol>
	</li>
</ol>
3. Harvesting samples for the liquid culture detection system
NOTE: On the day of infection, extracellular mycobacteria are removed by washing, and intracellular mycobacteria are harvested by lysis of one well of macrophages (3 h sample) to determine the initial amount phagocytosed as a baseline control for infection. At subsequent times both the medium, cell lysate, and washes are combined to measure total mycobacterial growth. Extracellular and intracellular growth can also be assessed separately if desired.
<ol>
	<li>Harvesting 3 h sample to determine TTP
	<ol>
		<li>Wash off extracellular mycobacteria from all the wells after the initial 3 h of infection as outlined in step 2.3.3. Add 1 mL of fresh media to the 3 h control well to equalize the lysate volume with those of later time points. 
		&#8203;NOTE: See step 3.2.7 if extracellular mycobacteria are to be excluded from the analysis.</li>
	</ol>
	</li>
	<li>Sample collection
	<ol>
		<li>Warm MB broth and instrument culture bottles to bring them to room temperature.</li>
		<li>Transfer the medium from the 12-well plate to the corresponding labeled conical tubes.</li>
		<li>Add 500 &#181;L of sterile lysis buffer (0.1% Triton x-100 in PBS filtered through a sterile 0.2 &#181;m filter) to each well for 10 min.</li>
		<li>Gently scrape the cells from the well with a sterile scraper and combine with the medium in the appropriate conical tube.</li>
		<li>Wash the well with 0.5 mL of sterile PBS and transfer to the appropriate tube.</li>
		<li>Gently pass each sample through a needle and syringe (25 G) 6-8 times to break up the clumps. Dilute samples 1:10 in MB broth; 100 &#181;L sample + 900 &#181;L MB medium.</li>
		<li>At the required times/days (usually between 1 to 8 days), harvest the remaining samples by following steps 3.2.1-3.2.6 above. 
		&#8203;NOTE: Investigators may prefer to exclude extracellular mycobacteria from their analysis, in which case, in step 3.2.2 above, the medium from each well is discarded, and macrophages are washed several times before adding lysis buffer.</li>
	</ol>
	</li>
	<li>Inoculating and loading instrument culture bottles 
	NOTE: Details of the liquid culture instrument and related consumables are provided in the Table of Materials.
	<ol>
		<li>Sterilize the rubber cap of the instrument culture bottle with tissue paper soaked in 70% alcohol and allow it to air dry. 
		NOTE: This step needs to be carried out in the BSC.</li>
		<li>Prepare bottles by transferring enough Nutrient supplements for all the samples into a conical tube (0.5 mL/bottle). Use a needle and syringe to inject 0.5 mL of Nutrient supplement into the instrument culture bottle.</li>
		<li>Pipette 500 &#181;L of the diluted sample (1:10) into a 1 mL V-bottomed tube.</li>
		<li>Use a needle and syringe to inject the 500 &#181;L of sample into the assigned instrument culture bottle.</li>
		<li>Sterilize the rubber cap of the instrument culture bottle with tissue paper soaked in 70% alcohol and allow it to air dry. Wipe the bottles with tissue paper soaked in 70% alcohol before removal from the BSC.</li>
		<li>Carefully transport bottles from the biosafety cabinet to the instrument for loading.</li>
		<li>Press the loading button on the automated microbial detection system.</li>
		<li>Scan the barcodes on instrument culture bottles and place the bottles into the detection system incubator at 37 &#176;C for up to 42 days. Read and record the time taken to reach positivity from the instrument screen. 
		NOTE: The barcode allows the instrument to identify the bottle and link reflectance readings with a particular bottle.</li>
		<li>Calculate percentage time to positivity (TTP) by comparing the TTP of the initial intracellular inoculum (Day 0) to that of macrophages cultured for the indicated times. A positive change in percentage TTP means mycobacterial growth13. 
		For example, for day 3: 
		Percentage change in time to positivity = <img alt="Equation 1" src="/files/ftp_upload/62838/62838eq01.jpg" /></li>
	</ol>
	</li>
</ol>

<ol>
	<li>WHO. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Global+Tuberculosis+Report.">Global Tuberculosis Report.</a> World Health Organization. , (2020).</li><li>Russell, D. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mycobacterium+tuberculosis+and+the+intimate+discourse+of+a+chronic+infection.">Mycobacterium tuberculosis and the intimate discourse of a chronic infection.</a> Immunological Reviews. 240 (1), 252-268 (2011).</li><li>Young, C., Walzl, G., Du Plessis, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Therapeutic+host-directed+strategies+to+improve+outcome+in+tuberculosis.">Therapeutic host-directed strategies to improve outcome in tuberculosis.</a> Mucosal Immunology. 13 (2), 190-204 (2020).</li><li>Angeby, K. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Evaluation+of+the+BacT/ALERT+3D+system+for+recovery+and+drug+susceptibility+testing+of+Mycobacterium+tuberculosis.">Evaluation of the BacT/ALERT 3D system for recovery and drug susceptibility testing of Mycobacterium tuberculosis.</a> Clinical Microbiology and Infection. 9 (11), 1148-1152 (2003).</li><li>Asmar, S., Drancourt, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Rapid+culture-based+diagnosis+of+pulmonary+tuberculosis+in+developed+and+developing+countries.">Rapid culture-based diagnosis of pulmonary tuberculosis in developed and developing countries.</a> Frontiers in Microbiology. 6, 1184 (2015).</li><li>Diacon, A. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Time+to+liquid+culture+positivity+can+substitute+for+colony+counting+on+agar+plates+in+early+bactericidal+activity+studies+of+antituberculosis+agents.">Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents.</a> Clinical Microbiology and Infection. 18 (7), 711-717 (2012).</li><li>Diacon, A. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Time+to+positivity+in+liquid+culture+predicts+colony+forming+unit+counts+of+Mycobacterium+tuberculosis+in+sputum+specimens.">Time to positivity in liquid culture predicts colony forming unit counts of Mycobacterium tuberculosis in sputum specimens.</a> Tuberculosis. 94 (2), 148-151 (2014).</li><li>O'Sullivan, D. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Evaluation+of+liquid+culture+for+quantitation+of+Mycobacterium+tuberculosis+in+murine+models.">Evaluation of liquid culture for quantitation of Mycobacterium tuberculosis in murine models.</a> Vaccine. 25 (49), 8203-8205 (2007).</li><li>Heinrichs, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mycobacterium+tuberculosis+Strains+H37ra+and+H37rv+have+equivalent+minimum+inhibitory+concentrations+to+most+antituberculosis+drugs.">Mycobacterium tuberculosis Strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs.</a> International Journal of Mycobacteriology. 7 (2), 156-161 (2018).</li><li>Sorrentino, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Development+of+an+intracellular+screen+for+new+compounds+able+to+inhibit+mycobacterium+tuberculosis+growth+in+human+macrophages.">Development of an intracellular screen for new compounds able to inhibit mycobacterium tuberculosis growth in human macrophages.</a> Antimicrobial Agents and Chemotherapy. 60 (1), 640-645 (2016).</li><li>O'Leary, S. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cigarette+smoking+impairs+human+pulmonary+immunity+to+Mycobacterium+tuberculosis.">Cigarette smoking impairs human pulmonary immunity to Mycobacterium tuberculosis.</a> American Journal of Respiratory and Critical Care Medicine. 190 (12), 1430-1436 (2014).</li><li>Ryan, R. C., O'Sullivan, M. P., Keane, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mycobacterium+tuberculosis+infection+induces+non-apoptotic+cell+death+of+human+dendritic+cells.">Mycobacterium tuberculosis infection induces non-apoptotic cell death of human dendritic cells.</a> BMC Microbiology. 11, 237 (2011).</li><li>Keane, J., Remold, H. G., Kornfeld, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Virulent+mycobacterium+tuberculosis+strains+evade+apoptosis+of+infected+alveolar+macrophages.">Virulent mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages.</a> The Journal of Immunology. 164 (4), 2016-2020 (2000).</li><li>Gao, X. F., Yang, Z. W., Li, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Adjunctive+therapy+with+interferon-gamma+for+the+treatment+of+pulmonary+tuberculosis:+a+systematic+review.">Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review.</a> International Journal of Infectious Diseases. 15 (9), 594-600 (2011).</li><li>Thorpe, T. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=BacT/Alert:+an+automated+colorimetric+microbial+detection+system.">BacT/Alert: an automated colorimetric microbial detection system.</a> Journal of Clinical Microbiology. 28 (7), 1608-1612 (1990).</li><li>Gleeson, L. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cutting+edge:+Mycobacterium+tuberculosis+induces+aerobic+glycolysis+in+human+alveolar+macrophages+that+is+required+for+control+of+intracellular+bacillary+replication.">Cutting edge: Mycobacterium tuberculosis induces aerobic glycolysis in human alveolar macrophages that is required for control of intracellular bacillary replication.</a> The Journal of Immunology. 196 (6), 2444-2449 (2016).</li><li>O'Connor, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Inhalable+poly(lactic-co-glycolic+acid)+(PLGA)+microparticles+encapsulating+all-trans-Retinoic+acid+(ATRA)+as+a+host-directed,+adjunctive+treatment+for+Mycobacterium+tuberculosis+infection.">Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection.</a> European Journal of Pharmaceutics and Biopharmaceutics. 134, 153-165 (2019).</li><li>O'Connor, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Sharpening+nature's+tools+for+efficient+tuberculosis+control:+A+review+of+the+potential+role+and+development+of+host-directed+therapies+and+strategies+for+targeted+respiratory+delivery.">Sharpening nature's tools for efficient tuberculosis control: A review of the potential role and development of host-directed therapies and strategies for targeted respiratory delivery.</a> Advanced Drug Delivery Reviews. 102, 33-54 (2016).</li><li>Rodriguez, D. C., Ocampo, M., Salazar, L. M., Patarroyo, M. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Quantifying+intracellular+Mycobacterium+tuberculosis:+An+essential+issue+for+in+vitro+assays.">Quantifying intracellular Mycobacterium tuberculosis: An essential issue for in vitro assays.</a> Microbiologyopen. 7 (2), 00588 (2018).</li><li>Ortalo-Magne, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Molecular+composition+of+the+outermost+capsular+material+of+the+tubercle+bacillus.">Molecular composition of the outermost capsular material of the tubercle bacillus.</a> Microbiology. 141, 1609-1620 (1995).</li><li>Stokes, R. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+glycan-rich+outer+layer+of+the+cell+wall+of+Mycobacterium+tuberculosis+acts+as+an+antiphagocytic+capsule+limiting+the+association+of+the+bacterium+with+macrophages.">The glycan-rich outer layer of the cell wall of Mycobacterium tuberculosis acts as an antiphagocytic capsule limiting the association of the bacterium with macrophages.</a> Infection and Immunity. 72 (10), 5676-5686 (2004).</li><li>O'Sullivan, M. P., O'Leary, S., Kelly, D. M., Keane, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+caspase-independent+pathway+mediates+macrophage+cell+death+in+response+to+Mycobacterium+tuberculosis+infection.">A caspase-independent pathway mediates macrophage cell death in response to Mycobacterium tuberculosis infection.</a> Infection and Immunity. 75 (4), 1984-1993 (2007).</li><li>Cheon, S. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Bactericidal+activity+in+whole+blood+as+a+potential+surrogate+marker+of+immunity+after+vaccination+against+tuberculosis.">Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis.</a> Clinical and Diagnostic Laboratory Immunology. 9 (4), 901-907 (2002).</li><li>Nathan, C., Barry, C. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=TB+drug+development:+immunology+at+the+table.">TB drug development: immunology at the table.</a> Immunological Reviews. 264 (1), 308-318 (2015).</li><li>Bowness, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+relationship+between+Mycobacterium+tuberculosis+MGIT+time+to+positivity+and+cfu+in+sputum+samples+demonstrates+changing+bacterial+phenotypes+potentially+reflecting+the+impact+of+chemotherapy+on+critical+sub-populations.">The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations.</a> Journal of Antimicrobial Chemotherapy. 70 (2), 448-455 (2015).</li><li>Basu Roy, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=An+auto-luminescent+fluorescent+BCG+whole+blood+assay+to+enable+evaluation+of+paediatric+mycobacterial+responses+using+minimal+blood+volumes.">An auto-luminescent fluorescent BCG whole blood assay to enable evaluation of paediatric mycobacterial responses using minimal blood volumes.</a> Frontiers in Pediatrics. 7, 151 (2019).</li><li>Christophe, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=High+content+screening+identifies+decaprenyl-phosphoribose+2'+epimerase+as+a+target+for+intracellular+antimycobacterial+inhibitors.">High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.</a> PLoS Pathogens. 5 (10), 1000645 (2009).</li><li>Franzblau, S. G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Comprehensive+analysis+of+methods+used+for+the+evaluation+of+compounds+against+Mycobacterium+tuberculosis.">Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.</a> Tuberculosis. 92 (6), 453-488 (2012).</li></ol>

The authors have nothing to disclose.

The authors have used the liquid culture method described in this protocol to monitor Mtb growth in monocyte-derived macrophages and alveolar macrophages and THP-1 cells differentiated with PMA11,16,17. This technique can also be modified for use with non-adherent cells12. More recently, the instrument was also used in preclinical studies to evaluate inhaled all-trans retinoic acid (AtRA) as an HDT for TB...

Mycobacterium tuberculosis (Mtb), the causative agent of TB, was the most significant infectious disease killer globally in 20191. To evade host defenses, Mtb subverts the mycobactericidal activity of innate immune cells such as macrophages and dendritic cells (DCs), allowing it to persist intracellularly and replicate2. The lack of an effective vaccine to prevent adult pulmonary TB and the increasing emergence of drug-resistant strains highlight the urgent need for new therapies.
Adjunctive host-directed therapies (HDT) could shorten treatment time and help overcome resistance3. Preclinical assessment of HDT candidates in vitro to determine mycobactericidal activity within macrophages often relies on the quantification of Mtb growth by colony-forming units (CFU) on solid agar plates. This is a slow, labor-intensive assay that does not lend itself to rapid screening of drugs. Commercially available automated, broth-based microbial detection systems are more commonly used in clinical microbiology laboratories for detection and drug susceptibility testing of Mtb and other mycobacterial species in clinical specimens4. These instruments measure growth indirectly based on the bacterial metabolic activity leading to physical changes in the culture media (change in CO2 or O2 levels or pressure) monitored over time5. The readout is time to positivity (TPP), which has previously been shown to correlate with Mtb CFU in sputum specimens of TB patients in response to treatment6,7 and in lysates of infected murine lung and spleen8. In addition, liquid culture detection systems have been used to measure the effect of conventional pathogen-directed therapies on the growth of mycobacteria in axenic culture and cultured macrophages9,10. The instrument has also been used to investigate the innate ability of dendritic cells and of alveolar macrophages to control intracellular growth of Mtb11,12. This experimental protocol demonstrates that a liquid culture diagnostic system can be adapted to perform preclinical screening of HDT for TB in cultured macrophages. Compared to CFU enumeration, the main advantage of this technique is that it considerably reduces the experimental labor and time required to quantify intracellular mycobacterial growth/survival. This technique relies on access to an automated culture instrument that can be used to assess intracellular mycobacterial survival in immune cells treated with a broad range of pharmacological reagents targeting cellular functions to boost host immunity.

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>IX51 Fluorescent Microscope</td>
			<td>Olympus, Japan</td>
			<td>N/A</td>
			<td>AFB detection and imaging</td>
		</tr>
		<tr>
			<td>2 mL microtube, flat bottom, screw cap, sterile</td>
			<td>Sarstedt, North Carolina, USA</td>
			<td>72.694.006</td>
			<td>Mtb infection of macropahges</td>
		</tr>
		<tr>
			<td>5 mL syringe, Luer lock</td>
			<td>BD Biosciences, San Jose, CA, USA</td>
			<td>SZR-150-031K</td>
			<td>Mtb infection of macropahges/CFU</td>
		</tr>
		<tr>
			<td>50 mL tube, sterile</td>
			<td>Sarstedt, North Carolina, USA</td>
			<td>62.547.254</td>
			<td>Mtb infection of macropahges</td>
		</tr>
		<tr>
			<td>all-trans-Retinoic Acid (ATRA) &#8805;98% (HPLC)</td>
			<td>Sigma Aldrich, Missouri, USA</td>
			<td>R2625</td>
			<td>Host directed therapy candidate</td>
		</tr>
		<tr>
			<td>BacT/ALERT 3D Microbial Detection System</td>
			<td>Biomerieux ( Hampshire, UK)</td>
			<td>247001</td>
			<td>Broth-based colormetric detection system</td>
		</tr>
		<tr>
			<td>BACT/ALERT MP&#160; BACT/ALERT MP Nutrient Supplement</td>
			<td>Biomerieux ( Hampshire, UK)</td>
			<td>414997</td>
			<td>Broth-based colormetric detection assay</td>
		</tr>
		<tr>
			<td>BACT/ALERT MP culture bottles</td>
			<td>Biomerieux ( Hampshire, UK)</td>
			<td>419744</td>
			<td>Broth-based colormetric detection assay</td>
		</tr>
		<tr>
			<td>BD BBL Middlebrook ADC Enrichment, 20 mL</td>
			<td>BD Biosciences, San Jose, CA, USA</td>
			<td>M0553</td>
			<td>Mycobacterium liquid culture</td>
		</tr>
		<tr>
			<td>BD BBL Middlebrook OADC Enrichment, 20mL</td>
			<td>BD Biosciences, San Jose, CA, USA</td>
			<td>M0678</td>
			<td>Colony Forming Units</td>
		</tr>
		<tr>
			<td>Cell scraper, 25 cm</td>
			<td>Sarstedt, North Carolina, USA</td>
			<td>83.1830</td>
			<td>Harvest of lmacrophage lysates</td>
		</tr>
		<tr>
			<td>Corning Syringe Filter, 0.2 &#181;m</td>
			<td>Corning Incorporated, Germany</td>
			<td>431219</td>
			<td>Sterilization of lysis buffer</td>
		</tr>
		<tr>
			<td>Cover glass (borosilicate), 24 x 50 mm, #1.5 thickness</td>
			<td>VWR International Limited</td>
			<td>631 - 0147</td>
			<td></td>
		</tr>
		<tr>
			<td>Cycloheximide, from microbial</td>
			<td>Sigma Aldrich, Missouri, USA</td>
			<td>C7698</td>
			<td>Colony Forming Units</td>
		</tr>
		<tr>
			<td>Dako Fluorescent Mounting Medium</td>
			<td>Agilent Technologies Ireland Limited</td>
			<td>S3023</td>
			<td>Antifade mounting medium</td>
		</tr>
		<tr>
			<td>Dulbecco&#8217;s Phosphate Buffered Saline</td>
			<td>Sigma Aldrich, Missouri, USA</td>
			<td>D8537</td>
			<td>Mtb infection of macropahges</td>
		</tr>
		<tr>
			<td>Fetal Bovine Serum, Gibco</td>
			<td>Thermo Fisher, Massachusetts, USA</td>
			<td>10270106</td>
			<td>Macrophage cell culture</td>
		</tr>
		<tr>
			<td>Glycerol, Difco</td>
			<td>BD Biosciences, San Jose, CA, USA</td>
			<td>228220</td>
			<td>Colony Forming Units</td>
		</tr>
		<tr>
			<td>Hoescht 33342 (bisBenzimide H 33342 trihydrochloride)</td>
			<td>Sigma Aldrich, Missouri, USA</td>
			<td>B2261</td>
			<td>Nuclear stain</td>
		</tr>
		<tr>
			<td>IFN&#947;, recombinant human</td>
			<td>R&#38;D Systems Inc, Minnesota, USA</td>
			<td>285-IF</td>
			<td>Host directed therapy candidate</td>
		</tr>
		<tr>
			<td>Labtek 2-well chamber slide, sterile, Nunc</td>
			<td>Thermo Fisher, Massachusetts, USA</td>
			<td>TKT-210-150R</td>
			<td>Mtb infection of macropahges</td>
		</tr>
		<tr>
			<td>L-Asparagine, anhydrous</td>
			<td>Sigma Aldrich, Missouri, USA</td>
			<td>A4159</td>
			<td>Colony Forming Units</td>
		</tr>
		<tr>
			<td>Linezolid</td>
			<td>Sigma Aldrich, Missouri, USA</td>
			<td>PZ0014</td>
			<td>Antibiotic</td>
		</tr>
		<tr>
			<td>Microlance Hypodermic Needle 25 G</td>
			<td>BD Biosciences, San Jose, CA, USA</td>
			<td>300400</td>
			<td>Mtb infection of macropahges/CFU</td>
		</tr>
		<tr>
			<td>Middlebrook 7H10 Agar Base</td>
			<td>BD Biosciences, San Jose, CA, USA</td>
			<td>M0303</td>
			<td>Colony Forming Units</td>
		</tr>
		<tr>
			<td>Middlebrook 7H9 Broth Base</td>
			<td>BD Biosciences, San Jose, CA, USA</td>
			<td>M0178</td>
			<td>Mycobacterium liquid culture</td>
		</tr>
		<tr>
			<td>Modified Auramine O Stain and Decolourizer</td>
			<td>Scientific Device Laboratory, IL, USA</td>
			<td>345-250</td>
			<td>AFB stain</td>
		</tr>
		<tr>
			<td>Paraformaldehyde</td>
			<td>Sigma Aldrich, Missouri, USA</td>
			<td>158127</td>
			<td>Mtb infection of macropahges</td>
		</tr>
		<tr>
			<td>Petri dishes, 92 x 16mm (20/bag)</td>
			<td>Sarstedt, North Carolina, USA</td>
			<td>82.1473.001</td>
			<td>Colony Forming Units</td>
		</tr>
		<tr>
			<td>Phorbol 12-myristate 13-acetate (PMA)</td>
			<td>Sigma Aldrich, Missouri, USA</td>
			<td>P8139</td>
			<td>Macrophage cell culture</td>
		</tr>
		<tr>
			<td>Polysorbate 80, Difco</td>
			<td>BD Biosciences, San Jose, CA, USA</td>
			<td>231181</td>
			<td>Mycobacterium liquid culture</td>
		</tr>
		<tr>
			<td>RPMI-1640, Gibco</td>
			<td>Thermo Fisher, Massachusetts, USA</td>
			<td>52400025</td>
			<td>Macrophage cell culture</td>
		</tr>
		<tr>
			<td>Sterile Cell Spreader, L-Shaped</td>
			<td>Fisherbrand, Thermo Fisher, MA, USA</td>
			<td>RB-44103</td>
			<td>Colony Forming Units</td>
		</tr>
		<tr>
			<td>T25 TC flask, angled neck, filter cap, sterile, Nunc</td>
			<td>Thermo Fisher, Massachusetts, USA</td>
			<td>156367</td>
			<td>Mycobacterium liquid culture</td>
		</tr>
		<tr>
			<td>THP-1 cell line</td>
			<td>ATCC, Virginia, USA</td>
			<td>ATCC TIB-202</td>
			<td>Macrophage cell culture</td>
		</tr>
	</tbody>
</table>

an automated culture system for use in preclinical testing of host-directed therapies for tuberculosis

Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), was the most significant infectious disease killer globally until the advent of COVID-19. Mtb has evolved to persist in its intracellular environment, evade host defenses, and has developed resistance to many anti-tubercular drugs. One approach to solving resistance is identifying existing&#160;approved drugs that will boost the host immune response to Mtb. These drugs could then be repurposed as adjunctive host-directed therapies (HDT) to shorten treatment time and help overcome antibiotic resistance.
Quantification of intracellular Mtb growth in macrophages is a crucial aspect of assessing potential HDT. The gold standard for measuring Mtb growth is counting colony-forming units (CFU) on agar plates. This is a slow, labor-intensive assay that does not lend itself to rapid screening of drugs. In this protocol, an automated, broth-based culture system, which is more commonly used to detect Mtb in clinical specimens, has been adapted for preclinical screening of host-directed therapies. The capacity of the liquid culture assay system to investigate intracellular Mtb growth in macrophages treated with HDT was evaluated. The HDTs tested for their ability to inhibit Mtb growth were all-trans Retinoic acid (AtRA), both in solution and encapsulated in poly(lactic-co-glycolic acid) (PLGA) microparticles and the combination of interferon-gamma and linezolid. The advantages of this automated liquid culture-based technique over the CFU method include simplicity of setup, less labor-intensive preparation, and faster time to results (5-12 days compared to 21 days or more for agar plates).

The automated liquid culture instrument used in this study monitors CO2 levels every 10 min. A color change in the sensor at the bottom of the instrument bottle is measured colorimetrically and expressed as reflectance units. The instrument software then applies detection algorithms to calculate time to positivity (TTP), i.e., the number of days from inoculation until cultures are flagged as positive (Figure 1A). An inverse relationship between TTP and log10CFU (determi...

Watch this Scientific Journal Video about An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis at JoVE.com

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Rapid and efficient quantification of intracellular M. tuberculosis growth is crucial for pursuing improved therapies against tuberculosis (TB). This protocol describes a broth-based colorimetric detection assay using an automated liquid culture system to quantify Mtb growth in macrophages treated with candidate host-directed therapies.

Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), was the most significant infectious disease killer globally until the advent ...

an-automated-culture-system-for-use-preclinical-testing-host-directed

Research

JoVE Journal

Immunology and Infection

1.7K Views.  The University of Dublin. Rapid and efficient quantification of intracellular M. tuberculosis growth is crucial for pursuing improved therapies against tuberculosis (TB). This protocol describes a broth-based colorimetric detection assay using an automated liquid culture system to quantify Mtb growth in macrophages treated with candidate host-directed therapies.

Video: An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format

The rapid detection of antimicrobial resistance is important in the effort to control the increase in resistant Mycobacterium 
tuberculosis (Mtb). Antimicrobial susceptibility testing (AST) of Mtb has traditionally been performed by the agar method of proportion or by 
macrobroth testing on an instrument such as the BACTEC (Becton Dickinson, Sparks, MD), VersaTREK (TREK Diagnostics, Cleveland, OH) or BacT/ALERT (bioM&eacute;rieux, Hazelwood, MO). The agar proportion method, while considered the &#x201C;gold&#x201D; standard of AST, is labor intensive and requires calculation of resistance by performing colony counts on drug-containing agar as compared to drug-free agar. If there is &ge;1% growth on the drug-containing medium as compared to drug-free medium, the organism is considered resistant to that drug. The macrobroth methods require instrumentation and test break point ("critical") drug concentrations for the first line drugs (isoniazid, ethambutol, rifampin, and pyrazinamide). The method described here is commercially available in a 96 well microtiter plate format [MYCOTB (TREK Diagnostics)] and contains increasing concentrations of 12 antimicrobials used for treatment of tuberculosis including both first (isoniazid, rifampin, ethambutol) and second line drugs (amikacin, cycloserine, ethionamide, kanamycin, moxifloxacin, ofloxacin, para-aminosalicylic acid, rifabutin, and streptomycin). Pyrazinamide, a first line drug, is not included in the microtiter plate due to its need for acidic test conditions. Advantages of the microtiter system include both ease of set up and faster turn around time (14 days) compared with traditional agar proportion (21 days). In addition, the plate can be set up from inoculum prepared using either broth or solid medium. Since the microtiter plate format is new and since Mtb presents unique safety challenges in the laboratory, this protocol will describe how to safely setup, incubate and read the microtiter plate.

Antimicrobial susceptibility testing of Mycobacterium tuberculosis is challenging but critical for patient care. This microtiter plate format offers testing of 12 antimycobacterial drugs and provides minimum inhibitory concentration (MIC) values, which will aid in appropriate treatment.

The rapid detection of antimicrobial resistance is important in the effort to control the increase in resistant Mycobacterium 
tuberculosis (Mtb). ...

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Tuberculosis (TB) due to Mycobacterium tuberculosis (MTB) remains a major public health issue: the infection affects up to one third of the world population1, and almost two million people are killed by TB each year.2 Universal access to high-quality, patient-centered treatment for all TB patients is emphasized by WHO's Stop TB Strategy.3 The rapid detection of MTB in respiratory specimens and drug therapy based on reliable drug resistance testing results are a prerequisite for the successful implementation of this strategy. However, in many areas of the world, TB diagnosis still relies on insensitive, poorly standardized sputum microscopy methods. Ineffective TB detection and the emergence and transmission of drug-resistant MTB strains increasingly jeopardize global TB control activities.2
Effective diagnosis of pulmonary TB requires the availability - on a global scale - of standardized, easy-to-use, and robust diagnostic tools that would allow the direct detection of both the MTB complex and resistance to key antibiotics, such as rifampicin (RIF). The latter result can serve as marker for multidrug-resistant MTB (MDR TB) and has been reported in &gt; 95% of the MDR-TB isolates.4, 5 The rapid availability of reliable test results is likely to directly translate into sound patient management decisions that, ultimately, will cure the individual patient and break the chain of TB transmission in the community.2
Cepheid's (Sunnyvale, CA, U.S.A.) Xpert MTB/RIF assay6, 7 meets the demands outlined above in a remarkable manner. It is a nucleic-acids amplification test for 1) the detection of MTB complex DNA in sputum or concentrated sputum sediments; and 2) the detection of RIF resistance-associated mutations of the rpoB gene.8 It is designed for use with Cepheid's GeneXpert Dx System that integrates and automates sample processing, nucleic acid amplification, and detection of the target sequences using real-time PCR and reverse transcriptase PCR. The system consists of an instrument, personal computer, barcode scanner, and preloaded software for running tests and viewing the results.9 It employs single-use disposable Xpert MTB/RIF cartridges that hold PCR reagents and host the PCR process. Because the cartridges are self-contained, cross-contamination between samples is eliminated.6 Current nucleic acid amplification methods used to detect MTB are complex, labor-intensive, and technically demanding. The Xpert MTB/RIF assay has the potential to bring standardized, sensitive and very specific diagnostic testing for both TB and drug resistance to universal-access point-of-care settings3, provided that they will be able to afford it. In order to facilitate access, the Foundation for Innovative New Diagnostics (FIND) has negotiated significant price reductions. Current FIND-negotiated prices, along with the list of countries eligible for the discounts, are available on the web.10

The Xpert MTB/RIF test integrates sample decontamination, hands-free operation, on-board sample processing, and ultra-sensitive hemi-nested PCR for the simultaneous detection of Mycobacterium tuberculosis and rifampicin resistance, either in expectorated sputum or concentrated sputum sediments, in approximately two hours. Testing is standardized and requires only moderate laboratory infrastructure and training.

Tuberculosis (TB) due to Mycobacterium tuberculosis (MTB) remains a major public health issue: the infection affects up to one third of the world ...

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Zebrafish larvae are particularly amenable to whole animal small molecule screens1,2 due to their small size and relative ease of manipulation and observation, as well as the fact that compounds can simply be added to the bathing water and are readily absorbed when administered in a &lt;1% DMSO solution. Due to the optical clarity of zebrafish larvae and the availability of transgenic lines expressing fluorescent proteins in leukocytes, zebrafish offer the unique advantage of monitoring an acute inflammatory response in vivo. Consequently, utilizing the zebrafish for high-content small molecule screens aiming at the identification of immune-modulatory compounds with high throughput has been proposed3-6, suggesting inflammation induction scenarios e.g. localized nicks in fin tissue, laser damage directed to the yolk surface of embryos7 or tailfin amputation3,5,6. The major drawback of these methods however was the requirement of manual larva manipulation to induce wounding, thus preventing high-throughput screening. Introduction of the chemically induced inflammation (ChIn) assay8 eliminated these obstacles. Since wounding is inflicted chemically the number of embryos that can be treated simultaneously is virtually unlimited. Temporary treatment of zebrafish larvae with copper sulfate selectively induces cell death in hair cells of the lateral line system and results in rapid granulocyte recruitment to injured neuromasts. The inflammatory response can be followed in real-time by using compound transgenic cldnB::GFP/lysC::DsRED26,9 zebrafish larvae that express a green fluorescent protein in neuromast cells, as well as a red fluorescent protein labeling granulocytes.
In order to devise a screening strategy that would allow both high-content and high-throughput analyses we introduced robotic liquid handling and combined automated microscopy with a custom developed software script. This script enables automated quantification of the inflammatory response by scoring the percent area occupied by red fluorescent leukocytes within an empirically defined area surrounding injured green fluorescent neuromasts. Furthermore, we automated data processing, handling, visualization, and storage all based on custom developed MATLAB and Python scripts.
In brief, we introduce an automated HC/HT screen that allows testing of chemical compounds for their effect on initiation, progression or resolution of a granulocytic inflammatory response. This protocol serves a good starting point for more in-depth analyses of drug mechanisms and pathways involved in the orchestration of an innate immune response. In the future, it may help identifying intolerable toxic or off-target effects at earlier phases of drug discovery and thereby reduce procedural risks and costs for drug development.

Here we describe a novel high-content chemically induced inflammation assay aiming at the identification of immune-modulatory bioactives. We have successfully combined automated microscopy with custom developed software scripts enabling automated quantification of the inflammatory response as well as further data processing, analysis, mining, and storage.

Zebrafish larvae are particularly amenable to whole animal small molecule screens1,2 due to their small size and relative ease of manipulation and ...

Establishment of an In vitro System to Study Intracellular Behavior of Candida glabrata in Human THP-1 Macrophages

A cell culture model system, if a close mimic of host environmental conditions, can serve as an inexpensive, reproducible and easily manipulatable alternative to animal model systems for the study of a specific step of microbial pathogen infection. A human monocytic cell line THP-1 which, upon phorbol ester treatment, is differentiated into macrophages, has previously been used to study virulence strategies of many intracellular pathogens including Mycobacterium tuberculosis. Here, we discuss a protocol to enact an in vitro cell culture model system using THP-1 macrophages to delineate the interaction of an opportunistic human yeast pathogen Candida glabrata with host phagocytic cells. This model system is simple, fast, amenable to high-throughput mutant screens, and requires no sophisticated equipment. A typical THP-1 macrophage infection experiment takes approximately 24 hr with an additional 24-48 hr to allow recovered intracellular yeast to grow on rich medium for colony forming unit-based viability analysis. Like other in vitro model systems, a possible limitation of this approach is difficulty in extrapolating the results obtained to a highly complex immune cell circuitry existing in the human host. However, despite this, the current protocol is very useful to elucidate the strategies that a fungal pathogen may employ to evade/counteract antimicrobial response and survive, adapt, and proliferate in the nutrient-poor environment of host immune cells.

Establishment of an In vitro System to Study Intracellular Behavior of Candida glabrata in Human THP-1 Macrophages

The current article outlines a protocol to establish an in vitro cell culture model system to study the interaction of a facultative intracellular human fungal pathogen Candida glabrata with human macrophages which will be a useful tool to advance our knowledge of fungal virulence mechanisms.

A cell culture model system, if a close mimic of host environmental conditions, can serve as an inexpensive, reproducible and easily manipulatable ...

An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei

Coinfections naturally occur due to the geographic overlap of distinct types of pathogenic organisms. Concurrent infections most likely modulate the respective immune response to each single pathogen and may thereby affect pathogenesis and disease outcome. Coinfected patients may also respond differentially to anti-infective interventions. Coinfection between tuberculosis as caused by mycobacteria and the malaria parasite Plasmodium, both of which are coendemic in many parts of sub-Saharan Africa, has not been studied in detail. In order to approach the challenging but scientifically and clinically highly relevant question how malaria-tuberculosis coinfection modulate host immunity and the course of each disease, we established an experimental mouse model that allows us to dissect the elicited immune responses to both pathogens in the coinfected host. Of note, in order to most precisely mimic naturally acquired human infections, we perform experimental infections of mice with both pathogens by their natural routes of infection, i.e. aerosol and mosquito bite, respectively.

An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei

Tuberculosis and malaria are two of the most prevalent infections in humans and major causes of morbidity and mortality in impoverished populations in the tropics. We established an experimental model system to study outcome of malaria-tuberculosis coinfection in mice after challenge with both pathogens via their natural route of infection.

Coinfections naturally occur due to the geographic overlap of distinct types of pathogenic organisms. Concurrent infections most likely modulate the ...

Establishment of a High-throughput Setup for Screening Small Molecules That Modulate c-di-GMP Signaling in Pseudomonas aeruginosa

Bacterial resistance to traditional antibiotics has driven research attempts to identify new drug targets in recently discovered regulatory pathways. Regulatory systems that utilize intracellular cyclic di-GMP (c-di-GMP) as a second messenger are one such class of target. c-di-GMP is a signaling molecule found in almost all bacteria that acts to regulate an extensive range of processes including antibiotic resistance, biofilm formation and virulence. The understanding of how c-di-GMP signaling controls aspects of antibiotic resistant biofilm development has suggested approaches whereby alteration of the cellular concentrations of the nucleotide or disruption of these signaling pathways may lead to reduced biofilm formation or increased susceptibility of the biofilms to antibiotics. We describe a simple high-throughput bioreporter protocol, based on green fluorescent protein (GFP), whose expression is under the control of the c-di-GMP responsive promoter cdrA, to rapidly screen for small molecules with the potential to modulate c-di-GMP cellular levels in Pseudomonas aeruginosa (P. aeruginosa). This simple protocol can screen upwards of 3,500 compounds within 48 hours and has the ability to be adapted to multiple microorganisms.

Establishment of a High-throughput Setup for Screening Small Molecules That Modulate c-di-GMP Signaling in Pseudomonas aeruginosa

This article describes the high-throughput assay that has been successfully established to screen large libraries of small molecules for their potential ability to manipulate cellular levels of cyclic di-GMP in Pseudomonas aeruginosa, providing a new powerful tool for antibacterial drug discovery and compound testing.

Bacterial resistance to traditional antibiotics has driven research attempts to identify new drug targets in recently discovered regulatory pathways. ...

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is a leading cause of morbidity and mortality worldwide. With the increased spread of multi drug-resistant TB (MDR-TB), there is a real urgency to develop new therapeutic strategies against M. tuberculosis infections. Traditionally, compounds are evaluated based on their antibacterial activity under in vitro growth conditions in broth; however, results are often misleading for intracellular pathogens like M. tuberculosis since in-broth phenotypic screening conditions are significantly different from the actual disease conditions within the human body. Screening for inhibitors that work inside macrophages has been traditionally difficult due to the complexity, variability in infection, and slow replication rate of M. tuberculosis. In this study, we report a new approach to rapidly assess the effectiveness of compounds on the viability of M. tuberculosis in a macrophage infection model. Using a combination of a cytotoxicity assay and an in-broth M. tuberculosis viability assay, we were able to create a screening system that generates a comprehensive analysis of compounds of interest. This system is capable of producing quantitative data at a low cost that is within reach of most labs and yet is highly scalable to fit large industrial settings.

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

We have developed a modular high-throughput screening system for discovering novel compounds against Mycobacterium tuberculosis, targeting intracellular and in-broth growing bacteria as well as cytotoxicity against the mammalian host cell.

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is a leading cause of morbidity and mortality worldwide. With the increased spread ...

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

The eradication of tuberculosis disease requires drug regimens that can penetrate the multiple layers of complex pulmonary lesions. Drug distribution in the caseous cores of cavities and lesions is especially crucial because they harbor subpopulations of drug-tolerant bacteria also commonly referred to as persisters. Existing methods for the measurement of drug penetration in tuberculosis lesions involve costly and time-consuming in vivo pharmacokinetic studies coupled to bioanalytical or imaging techniques. The in vitro measurement of drug binding to caseum macromolecules was proposed as an alternative to such techniques since this binding hinders the passive diffusion of drug molecules through caseum. Rapid equilibrium dialysis is a fast and reliable system for performing plasma protein and tissue binding studies. In this protocol, we used a rapid equilibrium dialysis (RED) device to measure drug binding to homogenates of caseum that is excised from the lesions and cavities of tuberculosis-infected rabbits. The protocol also describes how to generate a surrogate matrix from lipid loaded THP-1 macrophages to use in place of caseum. This caseum/surrogate binding assay is an important tool in tuberculosis drug discovery and can be adapted to help study drug distribution in lesions or abscesses caused by other diseases.

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Here we describe a rapid equilibrium dialysis (RED) method to measure drug binding to caseum from pulmonary tuberculosis lesions and cavities. The protocol is also used with a foamy macrophage-derived matrix that is an effective surrogate to caseum.

The eradication of tuberculosis disease requires drug regimens that can penetrate the multiple layers of complex pulmonary lesions. Drug distribution in ...

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Plasma cells (PCs) secrete large amounts of antibodies and develop from B cells that have been activated. PCs are rare cells located in the bone marrow or mucosa and ensure humoral immunity. Due to their low frequency and location, the study of PCs is difficult in human. We reported a B to PC in vitro differentiation model using selected combinations of cytokines and activation molecules that allow to reproduce the sequential cell differentiation occurring in vivo. In this in vitro model, memory B cells (MBCs) will differentiate into pre-plasmablasts (prePBs), plasmablasts (PBs), early PCs and finally, into long-lived PCs, with a phenotype close to their counterparts in healthy individuals.&#160;We also built an open access bioinformatics tools to analyze the most prominent information from GEP data related to PC differentiation. These resources can be used to study human B to PC differentiation and in the current study, we investigated the gene expression regulation of epigenetic factors during human B to PC differentiation.

Using multi-step culture systems, we report an in vitro B cell to plasma cell differentiation model.

Plasma cells (PCs) secrete large amounts of antibodies and develop from B cells that have been activated. PCs are rare cells located in the bone marrow or ...

Use of the Invertebrate Galleria mellonella as an Infection Model to Study the Mycobacterium tuberculosis Complex

Tuberculosis is the leading global cause of infectious disease mortality and roughly a quarter of the world&#8217;s population is believed to be infected with Mycobacterium tuberculosis. Despite decades of research, many of the mechanisms behind the success of M. tuberculosis as a pathogenic organism remain to be investigated, and the development of safer, more effective antimycobacterial drugs are urgently needed to tackle the rise and spread of drug resistant tuberculosis. However, the progression of tuberculosis research is bottlenecked by traditional mammalian infection models that are expensive, time consuming, and ethically challenging. Previously we established the larvae of the insect Galleria mellonella (greater wax moth) as a novel, reproducible, low cost, high-throughput and ethically acceptable infection model for members of the M. tuberculosis complex. Here we describe the maintenance, preparation, and infection of G. mellonella with bioluminescent Mycobacterium bovis BCG lux. Using this infection model, mycobacterial dose dependent virulence can be observed, and a rapid readout of in vivo mycobacterial burden using bioluminescence measurements is easily achievable and reproducible. Although limitations exist, such as the lack of a fully annotated genome for transcriptomic analysis, ontological analysis against genetically similar insects can be carried out. As a low cost, rapid, and ethically acceptable model for tuberculosis, G. mellonella can be used as a pre-screen to determine drug efficacy and toxicity, and to determine comparative mycobacterial virulence prior to the use of conventional mammalian models. The use of the G. mellonella-mycobacteria model will lead to a reduction in the substantial number of animals currently used in tuberculosis research.

Use of the Invertebrate Galleria mellonella as an Infection Model to Study the Mycobacterium tuberculosis Complex

Galleria mellonella was recently established as a reproducible, cheap, and ethically acceptable infection model for the Mycobacterium tuberculosis complex. Here we describe and demonstrate the steps taken to establish successful infection of G. mellonella with bioluminescent Mycobacterium bovis BCG lux.

Tuberculosis is the leading global cause of infectious disease mortality and roughly a quarter of the world&#8217;s population is believed to be infected ...